Navigation Links
Rigel to Present at Keystone Symposia Conference
Date:1/23/2009

SOUTH SAN FRANCISCO, Calif., Jan. 23 /PRNewswire-FirstCall/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that it will be presenting at the Keystone Symposia conference on Multiple Sclerosis taking place this week in Santa Fe, New Mexico.

Presentation Date: Sunday, January 25, 2009

Time: 2:30 - 4:30pm

Session: Workshop 2: New Therapeutic Approaches to MS

Presentation Title: The orally bioavailable Protein Kinase C Inhibitor RGE-80 can abrogate EAE disease induction and ameliorates disease in a therapeutic setting

About Rigel (http://www.rigel.com)

Rigel is a clinical-stage drug development company that discovers and develops novel, small-molecule drugs for the treatment of inflammatory/autoimmune diseases and cancer, as well as viral and metabolic diseases. Our pioneering research focuses on intracellular signaling pathways and related targets that are critical to disease mechanisms. Rigel's productivity has resulted in strategic collaborations with large pharmaceutical partners to develop and market our product candidates. Rigel has product development programs in inflammatory/autoimmune diseases such as rheumatoid arthritis, thrombocytopenia and asthma, as well as in cancer.

Contact: Raul Rodriguez

Phone: 650.624.1302

Email: invrel@rigel.com


'/>"/>
SOURCE Rigel Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1

Related medicine news :

1. Phase 2 Results of Rigels R788 Show Clinical Benefit in Diffuse Large B-Cell Lymphoma and CLL
2. Rigel to Present at the Piper Jaffray Annual Health Care Conference
3. Rigel to Present at the Oppenheimer 19th Annual Healthcare Conference
4. Rigel to Webcast Investor Update on October 27, 2008
5. QLT announces agreement to exclusively license the Atrigel(R) Technology to Reckitt Benckiser Pharmaceuticals Inc.
6. Rigel to Present at Collins Stewart Growth Conference
7. Rigel Announces First Quarter 2008 Financial Results
8. Rigel to Present at 8th Annual Fortis Bank Biotechnology Conference
9. Rigel Announces Participation in Upcoming Investor and Partnering Conferences
10. Daniel Magilavy, M.D. Joins Rigel as Vice President of Clinical Research
11. Rigel Announces Offering of 4,000,000 Shares of Common Stock
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2017)... Switzerland (PRWEB) , ... January 23, 2017 , ... ... lab and production applications. However, choosing the right method is paramount to success. ... occur more often in situations where multiple persons use the same equipment. Rare ...
(Date:1/23/2017)... (PRWEB) , ... January 23, 2017 , ... ... providing high-quality general gynecological care and gynecological services for women of ... personalized care for a wide variety of reproductive services from routine health screenings ...
(Date:1/23/2017)... ... 23, 2017 , ... “Some Infallible Characteristics of Christ”: a fascinating and ... Christ” is the creation of published author, Rev. Dr. Robert W. Thomas, the third ... a preacher for over nineteen, a pastor for over fifteen years. He is a ...
(Date:1/22/2017)... ... January 22, 2017 , ... Medical lab testing through hospitals ... of a simple test will take days to arrive to the end customer, having ... direct access to their lab tests, bypassing the cost and delay of traditional means. ...
(Date:1/21/2017)... ... January 21, 2017 , ... Phytocéane invites ... isolated from the rest of the world with ZANZIBAR SHOWER GEL. Inspired by the ... key ingredients, Virgin Coconut Oil and moisturizing vegetal coral to create this gentle, crystal-clear ...
Breaking Medicine News(10 mins):
(Date:1/23/2017)... Longer life expectancy and rising healthcare expenditure in developing countries are ... BCC Research reveals in its new report that markets in ... see strong growth due to rising government healthcare spending, increased levels of ... Continue Reading ... ...
(Date:1/23/2017)... Spain , January 23, 2017 ... clinical-stage biopharmaceutical company focused on treatments for calcification ... been enrolled in the Phase IIb "CaLIPSO Study" ... treatment of cardiovascular calcification (CVC) in end-stage-renal-disease (ESRD) ... patients, in the last stage of chronic kidney ...
(Date:1/22/2017)... , Saudi Arabia , January 22, 2017 ... US and UAE discuss ... , at the World Economic Forum   "The management ... by big data and powered by artificial intelligence and this trend is going ... the ,Hospital of the Future, at the concluding day of the 47 th ...
Breaking Medicine Technology: